HeartFlow
Decisive Coronary Care
IvaraX Analysis
HeartFlow provides an AI-driven diagnostic platform that transforms standard CT scans into detailed 3D cardiac models, enabling non-invasive assessment of coronary artery disease. The technology addresses limitations of conventional diagnostic methods that can result in false positives and negatives, and is backed by substantial clinical evidence and widespread institutional adoption.
Key Strengths
- +Extensive clinical validation through 600+ peer-reviewed publications demonstrating scientific rigor
- +Significant market traction with deployment across 1,400+ institutions globally
- +Comprehensive end-to-end platform covering identification, decision-making, and ongoing disease management
- +Non-invasive approach that can reduce unnecessary invasive procedures and improve patient experience
- +Strong reimbursement infrastructure facilitating healthcare system adoption
Ideal For
- →Hospital cardiology departments seeking to enhance non-invasive CAD diagnostic capabilities
- →Healthcare systems looking to reduce unnecessary invasive cardiac procedures
- →Interventional cardiologists requiring detailed pre-procedural planning insights
- →Preventive cardiology programs focused on early detection and long-term disease management
Things to Consider
- !Implementation requires existing CCTA imaging infrastructure and capabilities
- !Some platform functions have limited availability in certain markets (Canada and Japan only support FFR CT and Planner functions)
- !Healthcare providers should evaluate integration requirements with existing clinical workflows and systems
About HeartFlow
HeartFlow is a medical technology company headquartered in Mountain View, California, dedicated to transforming the diagnosis and management of coronary artery disease (CAD). The company has developed a first-of-its-kind AI-powered platform that converts standard Coronary CT Angiography (CCTA) scans into detailed, personalized 3D models of the heart. This technology enables clinicians to assess anatomy, physiology, and blood flow non-invasively, helping to identify disease earlier and create individualized treatment pathways for patients with suspected CAD. The HeartFlow One platform encompasses multiple analytical capabilities including Roadmap™ Analysis for efficient CCTA reading and early CAD detection, FFR CT Analysis for assessing blood flow and determining revascularization benefits, and Plaque Analysis for quantifying and characterizing coronary plaque to inform risk management. With over 500,000 patients treated across more than 1,400 institutions, and supported by more than 600 peer-reviewed publications, HeartFlow has established itself as a leader in AI-driven cardiac diagnostics. The company's solutions are cleared for clinical use in 43 countries and regions, with 99.5% of US lives covered by reimbursement.
Why Choose HeartFlow
- AI-powered 3D heart modeling provides comprehensive assessment of anatomy, physiology, and blood flow from non-invasive CCTA scans
- Proven clinical validation with over 600 peer-reviewed publications supporting the technology
- Extensive market presence with adoption across 1,400+ healthcare institutions and 500,000+ patients treated
- Comprehensive platform offering multiple analysis types (Roadmap, FFR CT, Plaque) for complete CAD management
- Strong reimbursement coverage with 99.5% of US lives covered, reducing financial barriers to adoption
Services
AI-powered cardiac imaging analysisFFR CT AnalysisPlaque AnalysisRoadmap AnalysisCCTA Support Services
Technologies
AI3D modelingCoronary CTA imagingFFR CT
Tech Stack(detected from website)
AI/Machine Learning for cardiac analysis3D modeling and visualization technologyMedical imaging processing (CCTA)Cloud-based platform infrastructure
Industries Served
Categories
Company Info
- Headquarters
- Mountain View, CA, US
